Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1662385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Peili Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: beta Catenin, Colorectal Neoplasms, Prodrugs, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction
Hyperactivation of the Wnt/β-catenin pathway serves as a central mechanism underlying tumor progression, immune evasion, and resistance to immune checkpoint inhibitor therapy in colorectal cancer (CRC). A pivotal contributor to this process is the binding of β-catenin to B-cell lymphoma 9 (BCL9), which promotes transcription of oncogenes and fosters an immune-suppressive tumor milieu. Consequently, targeting this interaction offers a promising approach to suppress tumor progression and potentiate antitumor immune responses.
Methods
We developed a peptide-based prodrug, Bcl9@TP, designed to competitively bind the BCL9 interface on β-catenin, destabilize the transcriptional complex, and suppress Wnt/β-catenin signaling. Its antitumor efficacy and immune potentiation were assessed in vitro using MC38 cells and in vivo in murine tumor models.
Results
In vitro , Bcl9@TP significantly inhibited MC38 cell proliferation by downregulating β-catenin and its downstream targets, inducing G1-phase cell cycle arrest. In vivo , Bcl9@TP treatment markedly reduced tumor burden, with a tumor growth inhibition (TGI) rate of ~62%, significantly higher than the control group. In contrast, anti-PD-1 monotherapy yielded a TGI of only 41%. Notably, combination therapy (Bcl9@TP plus anti-PD-1) produced a more pronounced antitumor effect, with the TGI reaching 82%. Importantly, Bcl9@TP demonstrated favorable systemic biocompatibility and safety.
Discussion
Our findings indicate that disrupting the β-catenin/BCL9 interaction with a peptide-based nanoprodrug represents a compelling strategy to suppress oncogenic signaling and enhance immunotherapy responses in CRC, providing a new angle to boost checkpoint sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Institute for Stem Cell & Regenerative Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, P., Shang, X., Wang, J., You, W., Qu, S., Yao, Y., & Zheng, X. (2025). Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1662385
Vancouver
Wang P, Shang X, Wang J, You W, Qu S, Yao Y, et al. Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1662385
BibTeX
@article{Wang2025,
author = {Wang, Peili and Shang, Xiao and Wang, Jinmei and You, Weiming and Qu, Shoufei and Yao, Yu and Zheng, Xiaoqiang},
title = {Disrupting β-Catenin/BCL9 interaction with a peptide prodrug boosts immunotherapy in colorectal cancer},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1662385}
}
EUVIMED